Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
<div><p paraid=”1424849640″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{9}”><strong>By Irene Yeh </strong></p></div><div><p paraid=”326437554″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{15}”><strong>January 29, 2026</strong> | Earlier this month at the J.P. Morgan Healthcare Conference, Eli Lilly Chairman and CEO David Ricks spoke at a fireside chat and presented what the company has planned for 2026, which also marks its 150th anniversary. This year is expected to be a productive one in terms of clinical trial activity, wider availability of medicines, and expansion into new therapeutic areas. </p></div><div><p paraid=”1509187804″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{107}”><strong>Anti-Obesity Drugs </strong></p></div><div><p paraid=”1827316575″ […]
A small molecule PTER-selective inhibitor reduces food intake and body weight
PTER (phosphotriesterase-related) is an amidohydrolase that mediates catabolism of the anorexigenic taurine metabolite N-acetyltaurine. However, the structural basis of PTER ligand binding and catalysis remains unknown, limiting our ability to harness this pathway therapeutically. Here, we solve crystal structures of a eukaryotic PTER in apo and product-bound forms. These structures uncover an unexpected pocket homology […]
Navigating the complex relationship between statins, GLP-1, and glycemic control
A study linking statins, the microbiome, and blood sugar control doesn’t change clinical practice The post Navigating the complex relationship between statins, GLP-1, and glycemic control appeared first on Peter Attia.
Incretin Based Therapy in Heart Failure with Preserved Ejection Fraction
Join the American Heart Association for an insightful session with Dr. Clyde Yancy and Dr. Dhruv Kazi. Recent clinical trials demonstrate the efficacy of incretin-based therapies (including GLP1-RA) in the care of HFpEF patients and their pivotal role in improving patient quality of life. Dr. Clyde Yancy discusses the latest evidence from these landmark trials […]
Arthur Brooks: Do GLP-1s Make Us Happy?
In my column last Monday, I wrote about how to make better New Year’s resolutions—ones that are less likely to flop, but that are also challenging enough to provide satisfaction. Why? Because accomplishing something with a degree of struggle is the way to realize joy. I gave the example of using GLP-1 drugs for weight […]
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading
More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.
‘Another self own’: Trump comment sparks internet rumors of president on Ozempic
President Donald Trump touted Friday his new health care plan, which he dubbed “The Great Health Care Plan” during a press conference from the White House, but his meandering remarks about a “friend” who took the weight-loss drug Ozempic quickly fueled online speculation about whether the president himself was using it. “A friend of mine […]
‘Shamed’ Oprah Winfrey ‘Blamed Herself’ for Packing on the Pounds Before Using Weight Loss Medications to Shed 50Lbs — And Now She Can’t Quit the Jabs
Oprah dropped about 50 pounds after going on GLP-1 drugs two and a half years ago, but then quickly gained back 20 pounds when she stopped taking them.
Signaling architecture of the glucagon-like peptide-1 receptor
The glucagon-like peptide-1 receptor (GLP-1R) is a class B1 G protein–coupled receptor and major therapeutic target in type 2 diabetes and obesity. Beyond its canonical role in Gαs/cAMP signaling, GLP-1R is increasingly recognized as an organizer of spatiotemporally defined signaling nanodomains, or “signalosomes.” This Review highlights our current knowledge on the mechanisms of assembly and […]
GLP-1 physiology and pharmacology along the gut-brain axis
Historically, antiobesity medications have been modestly effective at best, with side-effect profiles that limit compliance and often preclude the long-term therapy required to maintain weight loss. Recently developed therapies based on analogs of the gut hormone glucagon-like peptide-1 (GLP-1) have transformed the medical management of obesity, leading both to a degree of weight loss that […]